Literature DB >> 33048353

A Tutorial for Pharmacogenomics Implementation Through End-to-End Clinical Decision Support Based on Ten Years of Experience from PREDICT.

Michelle Liu1, Cindy L Vnencak-Jones2,3, Bartholomew P Roland4, Cheryl L Gatto4,5, Janos L Mathe6, Shari L Just6, Josh F Peterson7,8, Sara L Van Driest3,7, Asli O Weitkamp8.   

Abstract

Vanderbilt University Medical Center implemented pharmacogenomics (PGx) testing with the Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment (PREDICT) initiative in 2010. This tutorial reviews the laboratory considerations, technical infrastructure, and programmatic support required to deliver panel-based PGx testing across a large health system with examples and experiences from the first decade of the PREDICT initiative. From the time of inception, automated clinical decision support (CDS) has been a critical capability for delivering PGx results to the point-of-care. Key features of the CDS include human-readable interpretations and clinical guidance that is anticipatory, actionable, and adaptable to changes in the scientific literature. Implementing CDS requires that structured results from the laboratory be encoded in standards-based messages that are securely ingested by electronic health records. Translating results to guidance also requires an informatics infrastructure with multiple components: (1) to manage the interpretation of raw genomic data to "star allele" results to expected phenotype, (2) to define the rules that associate a phenotype with recommended changes to clinical care, and (3) to manage and update the knowledge base. Knowledge base management is key to processing new results with the latest guidelines, and to ensure that historical genomic results can be reinterpreted with revised CDS. We recommend that these components be deployed with institutional authorization, programmatic support, and clinician education to govern the CDS content and policies around delivery.
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2020        PMID: 33048353      PMCID: PMC7902340          DOI: 10.1002/cpt.2079

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.903


  30 in total

Review 1.  Accreditation of Individualized Quality Control Plans by the College of American Pathologists.

Authors:  Gerald A Hoeltge
Journal:  Clin Lab Med       Date:  2016-12-22       Impact factor: 1.935

2.  Implementation and obstacles of pharmacogenetics in clinical practice: An international survey.

Authors:  Elizabeth Abou Diwan; Ralph I Zeitoun; Lea Abou Haidar; Ingolf Cascorbi; Nathalie Khoueiry Zgheib
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

Review 3.  Population Diversity in Pharmacogenetics: A Latin American Perspective.

Authors:  Guilherme Suarez-Kurtz; Esteban J Parra
Journal:  Adv Pharmacol       Date:  2018-03-19

Review 4.  Pharmacogenomics in the clinic.

Authors:  Mary V Relling; William E Evans
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

Review 5.  The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?

Authors:  Honghong Zhang; Tanima De; Yizhen Zhong; Minoli A Perera
Journal:  Clin Pharmacol Ther       Date:  2019-08       Impact factor: 6.875

6.  Clinician Perspectives on Using Pharmacogenomics in Clinical Practice.

Authors:  Kim M Unertl; Habiba Jaffa; Julie R Field; Lisa Price; Josh F Peterson
Journal:  Per Med       Date:  2015       Impact factor: 2.512

7.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

Review 8.  Stakeholder views on pharmacogenomic testing.

Authors:  Haridarshan N Patel; Iulia D Ursan; Patrick M Zueger; Larisa H Cavallari; A Simon Pickard
Journal:  Pharmacotherapy       Date:  2013-10-24       Impact factor: 4.705

Review 9.  Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome.

Authors:  Dan M Roden; Sara L Van Driest; Jonathan D Mosley; Quinn S Wells; Jamie R Robinson; Joshua C Denny; Josh F Peterson
Journal:  Clin Pharmacol Ther       Date:  2018-03-13       Impact factor: 6.875

Review 10.  A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.

Authors:  Catrin O Plumpton; Daniel Roberts; Munir Pirmohamed; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

View more
  8 in total

Review 1.  Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.

Authors:  Cyrine E Haidar; Kristine R Crews; James M Hoffman; Mary V Relling; Kelly E Caudle
Journal:  Annu Rev Genomics Hum Genet       Date:  2022-05-10       Impact factor: 9.340

2.  A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, and VKORC1 Genes.

Authors:  Camille Tron; Régis Bouvet; Marie-Clémence Verdier; Fabien Lamoureux; Benjamin Hennart; Christèle Dubourg; Eric Bellissant; Marie-Dominique Galibert
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-22

3.  Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy.

Authors:  Ramzi G Salloum; Jeffrey R Bishop; Amanda L Elchynski; D Max Smith; Elizabeth Rowe; Kathryn V Blake; Nita A Limdi; Christina L Aquilante; Jill Bates; Amber L Beitelshees; Amber Cipriani; Benjamin Q Duong; Philip E Empey; Christine M Formea; J Kevin Hicks; Pawel Mroz; David Oslin; Amy L Pasternak; Natasha Petry; Laura B Ramsey; Allyson Schlichte; Sandra M Swain; Kristen M Ward; Kristin Wiisanen; Todd C Skaar; Sara L Van Driest; Larisa H Cavallari; Sony Tuteja
Journal:  Implement Sci Commun       Date:  2022-05-14

4.  Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.

Authors:  Ina Liko; Yee Ming Lee; Danielle L Stutzman; Allison B Blackmer; Kimberly M Deininger; Ann M Reynolds; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2021-03-04       Impact factor: 2.533

Review 5.  Pharmacogenomic Clinical Decision Support: A Review, How-to Guide, and Future Vision.

Authors:  Dyson T Wake; D Max Smith; Sadaf Kazi; Henry M Dunnenberger
Journal:  Clin Pharmacol Ther       Date:  2021-08-29       Impact factor: 6.903

Review 6.  Pharmacogenomic testing in paediatrics: Clinical implementation strategies.

Authors:  Charlotte I S Barker; Gabriella Groeneweg; Anke H Maitland-van der Zee; Michael J Rieder; Daniel B Hawcutt; Tim J Hubbard; Jesse J Swen; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2022-02-07       Impact factor: 3.716

Review 7.  Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example.

Authors:  David F Kisor; Natasha J Petry; David R Bright
Journal:  Pharmgenomics Pers Med       Date:  2021-05-18

8.  Documenting Pharmacogenomic Test Results in Electronic Health Records: Practical Considerations for Primary Care Teams.

Authors:  Roseann S Gammal; Lucas A Berenbrok; Philip E Empey; Mylynda B Massart
Journal:  J Pers Med       Date:  2021-12-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.